Briefs: Venus Remedies and GPT Healthcare

Venus Remedies secures marketing authorization in Philippines

FDA RMAT status for Affimed and Artiva’s lymphoma combo therapy

Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients

Shilpa Medicare’s JV Oncosol gets USFDA approval for IMKELDI

IMKELDI is an advanced liquid formulation of imatinib designed to provide dosing accuracy

Amalgamation of Gujarat Themis Biosyn with Themis Medicare

The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL

Lubrizol and Polyhose ink MoU to set up medical tube manufacturing facility in Tamil Nadu

This agreement reinforces Lubrizol’s commitment to Make-In-India and broadens a previously committed US$ 350 million investment to support local manufacturing

Shilpa Medicare Q2 FY25 consolidated PAT up 1,008% at Rs. 18 Cr

Shilpa Medicare’s acceptance by USFDA of NDA filed by its CDMO partner Unicycive for Oxylanthanum Carbonate

Henkel, Covestro and Quad Industries collaborate for advanced medical wearables based on printed electronics

Combined capabilities to drive novel healthcare applications presented at MEDICA 2024

Medanta to operate and manage 750 bed super speciality hospital in Pitampura, New Delhi

Medanta is expected to incur a project capex of ~Rs. 600 crores in next 3-4 years

Venus Remedies gets approval from Malaysian PIC/S GMP for pre-filled syringe facility

The recognition from Malaysia's NPRA, a member of PIC/S, opens doors to new global business opportunities